John P. Schmid - 16 Nov 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
16 Nov 2023
Net transactions value
+$9,815
Form type
4
Filing time
17 Nov 2023, 18:35:56 UTC
Previous filing
16 Jun 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $9,815 +6,500 $1.51 6,500 16 Nov 2023 By: The Schmid Family Trust dated August 15, 2017 F1
holding XERS Common Stock 63,159 16 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.